As of January 22, 2020, 571 cases of 2019-nCoV were reported in China, with 95 severe and 17 fatal cases. There is currently no vaccine or antiviral treatment for coronaviruses. Three methods are used to identify potential antiviral treatments: testing existing broad-spectrum antiviral drugs, screening chemical libraries, and redeveloping specific drugs based on coronavirus genome and biophysical properties. Potential treatments include lopinavir/ritonavir, nucleoside analogs, neuraminidase inhibitors, remdesivir, peptide EK1, arbidol, RNA synthesis inhibitors, anti-inflammatory drugs, and traditional Chinese medicine such as ShuFengJieDu Capsules and Lianhuaqingwen Capsules. However, their efficacy and safety for 2019-nCoV need further clinical confirmation. The first method involves testing existing broad-spectrum antiviral drugs, which have known pharmacokinetic and pharmacodynamic properties but lack specific anti-coronavirus effects. The second method screens chemical libraries for compounds with antiviral activity, including drugs with physiological and immunological effects. The third method redevelops specific drugs based on coronavirus genome and biophysical understanding, which may have in vitro or in vivo anti-coronavirus activity but require further evaluation in animal and human trials. According to guidelines, IFN-alpha and lopinavir/ritonavir are recommended for 2019-nCoV treatment. Remdesivir is considered a potential drug due to its effectiveness against MERS-CoV and completion of phase III clinical trials for Ebola. Neuraminidase inhibitors like oseltamivir are used for influenza but lack evidence for 2019-nCoV. Other drugs such as EK1, arbidol, and RNA synthesis inhibitors show in vitro activity. Traditional Chinese medicine may also have potential, but their efficacy and safety for 2019-nCoV need clinical confirmation. In summary, there are no specific antiviral drugs or vaccines for 2019-nCoV. All current drug options are based on experience with SARS, MERS, or other influenza viruses. Active symptomatic support remains key to treatment. The efficacy of these drugs needs further clinical confirmation.As of January 22, 2020, 571 cases of 2019-nCoV were reported in China, with 95 severe and 17 fatal cases. There is currently no vaccine or antiviral treatment for coronaviruses. Three methods are used to identify potential antiviral treatments: testing existing broad-spectrum antiviral drugs, screening chemical libraries, and redeveloping specific drugs based on coronavirus genome and biophysical properties. Potential treatments include lopinavir/ritonavir, nucleoside analogs, neuraminidase inhibitors, remdesivir, peptide EK1, arbidol, RNA synthesis inhibitors, anti-inflammatory drugs, and traditional Chinese medicine such as ShuFengJieDu Capsules and Lianhuaqingwen Capsules. However, their efficacy and safety for 2019-nCoV need further clinical confirmation. The first method involves testing existing broad-spectrum antiviral drugs, which have known pharmacokinetic and pharmacodynamic properties but lack specific anti-coronavirus effects. The second method screens chemical libraries for compounds with antiviral activity, including drugs with physiological and immunological effects. The third method redevelops specific drugs based on coronavirus genome and biophysical understanding, which may have in vitro or in vivo anti-coronavirus activity but require further evaluation in animal and human trials. According to guidelines, IFN-alpha and lopinavir/ritonavir are recommended for 2019-nCoV treatment. Remdesivir is considered a potential drug due to its effectiveness against MERS-CoV and completion of phase III clinical trials for Ebola. Neuraminidase inhibitors like oseltamivir are used for influenza but lack evidence for 2019-nCoV. Other drugs such as EK1, arbidol, and RNA synthesis inhibitors show in vitro activity. Traditional Chinese medicine may also have potential, but their efficacy and safety for 2019-nCoV need clinical confirmation. In summary, there are no specific antiviral drugs or vaccines for 2019-nCoV. All current drug options are based on experience with SARS, MERS, or other influenza viruses. Active symptomatic support remains key to treatment. The efficacy of these drugs needs further clinical confirmation.